In systematic reviews, VRE infections have demonstrated a two-fold increase in morbidity, mortality, and economic burden compared to vancomycin sensitive isolates, even after VRE treatments were made available.

Enterococcal endocarditis has a mortality rate of 11 to 35%, while the mortality rate for enterococcal bacteremia is 25% and for enterococcal meningitis is 20%.